Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The interest coverage ratio is N/A as of Tuesday, October 6, 2026.
INTEREST COVERAGE RATIO
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.33B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.31B
Interest Coverage Ratio
-100.93x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Interest Coverage Ratio
-11.07x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Interest Coverage Ratio
-1753.94x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Interest Coverage Ratio
7.70x
TTM Avg
6.59x
3Y Avg
5.19x
5Y Avg
6.41x
Market Cap
$1.42B
Interest Coverage Ratio
0.60x
TTM Avg
0.60x
3Y Avg
0.60x
5Y Avg
0.60x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.33B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | -100.93x | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -11.07x | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -1753.94x | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 7.70x | 6.59x | 5.19x | 6.41x |
| Kardigan, Inc. (KARD)vs › | $1.25B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 0.60x | 0.60x | 0.60x | 0.60x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -8.63x | N/A | N/A | N/A |
Interest Coverage
N/A
Debt/Equity
0.00
Current Ratio
35.85
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
